Related Experiment Video

Updated: Aug 8, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K

Lung Cancer - Standard Therapy and the Use of a Novel, Highly Effective, Well Tolerated, Treatment With Progesterone

Jerome H Check1,2, Trina Poretta3, Diane Check2

  • 1Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology & Infertility, Cooper Medical School of Rowan University, Camden, NJ, U.S.A.; laurie@ccivf.com.

Anticancer Research
|February 28, 2023
PubMed

Insights

Recent lung cancer therapies target tumor mutations for better outcomes. A novel approach using progesterone receptor antagonists shows potential for advanced lung cancer, warranting further clinical studies.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Lung cancer treatment advances focus on personalized profiling (genetic, epigenetic, immunologic).
  • Targeted therapies and immunotherapies (e.g., EGFR, KRAS, ALK inhibitors, PD-1/ligand blockade) have improved survival and palliation for specific patient groups.

Purpose of the Study:

  • To review lung cancer drug efficacy up to 2022.
  • To introduce progesterone receptor (PR) antagonists targeting progesterone induced blocking factor (PIBF) as a novel therapeutic strategy.
  • To encourage large-scale clinical trials to validate PR antagonist efficacy in advanced lung cancer.

Main Methods:

  • Review of existing literature on lung cancer therapies and drug efficacy.
  • Analysis of preliminary data from one murine study and five human cases on PR antagonists.
  • Proposal for future well-powered clinical studies.

Main Results:

  • Established targeted therapies and immunotherapies have demonstrated significant benefits for specific lung cancer mutations.
  • Preliminary data suggest PR antagonists may offer palliative and longevity benefits in advanced lung cancer patients with limited options.
  • Further research is needed to confirm these findings in larger patient cohorts.

Conclusions:

  • Personalized medicine has revolutionized lung cancer treatment.
  • PR antagonists represent a potential new avenue for treating advanced lung cancer, but require robust clinical validation.
  • Oncologists are encouraged to investigate PR antagonist therapy through well-designed clinical trials.
Keywords:
Non-small cell lung cancerantagonist/modulatorscheck-point inhibitorplatinum-based chemotherapyprogesterone receptorreviewsmall cell lung cancertyrosine kinase inhibitor

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy05:52

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

11.6K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
238
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
550
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
468
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
285